Skip to main content
SpringerLink
Log in

Screening for Prostate Cancer

  • Chapter
Urological Cancers

  • 384 Accesses

Conclusion

The dilemmas surrounding the value of screening and treatment in clinically localized prostate cancer remain unresolved. Recently published work from Scandinavia sheds some light into potential benefits of radical prostatectomy in preventing patients from dying from prostate cancer, although aggressive treatment did not improve overall survival compared with watchful waiting. Results from the now-merged ERSPC in Europe and PLCO in the U.S., the Protect study in the U.K., and the PIVOT study in the U.S. are awaited eagerly. It is reassuring for the medical community and prostate cancer patients worldwide that these long-standing dilemmas in the management of prostate are being resolved through large and robust randomized controlled trials supported by governments and funding institutions in Europe and the U.S.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public health paper No. 34. Geneva: World Health Organization, 1968.

    Google Scholar 

  2. Jenson OM, Esteve J, Renhard H. Cancer in the European Community and its member states. Eur J Cancer 1990;26:1167–1256.

    Article  Google Scholar 

  3. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin 2001;5:15–36.

    Article  Google Scholar 

  4. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100(5):892–899.

    Article  PubMed  Google Scholar 

  5. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008–2012.

    Article  PubMed  CAS  Google Scholar 

  6. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(special No. 1):R103–121.

    Article  PubMed  CAS  Google Scholar 

  7. Sakr WA. Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379–385.

    PubMed  CAS  Google Scholar 

  8. Häggman MJ, Macoska JA, Wojna KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997;158:12–22.

    Article  PubMed  Google Scholar 

  9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215–224.

    Article  PubMed  CAS  Google Scholar 

  10. Whitmore WF Jr. Localised prostate cancer: management and detection issues 1994. Lancet 1994;343:1263–1267.

    Article  PubMed  Google Scholar 

  11. Barnes RW. Survival with conservative therapy. JAMA 1969;210:331–332.

    Article  PubMed  CAS  Google Scholar 

  12. Johansson J, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective population based study in Sweden. JAMA 1997;227:467–471.

    Article  Google Scholar 

  13. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242–248.

    Article  PubMed  CAS  Google Scholar 

  14. Lu-Yao GL, Yao SL. Population based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906–910.

    Article  PubMed  CAS  Google Scholar 

  15. Albertsen PC, Frybeck DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626–631.

    Article  PubMed  CAS  Google Scholar 

  16. Albertsen PC, Hanley JA, Gleson DF, et al. A competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975–980.

    Article  PubMed  CAS  Google Scholar 

  17. Gann PH, Hennekens CH, Sampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA 1992;273:289–294.

    Article  Google Scholar 

  18. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence for success against cancer? JAMA 2000;283(2):2975–2978.

    Article  PubMed  CAS  Google Scholar 

  19. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int 2001;87(5):423–430.

    Article  PubMed  CAS  Google Scholar 

  20. Kranse R, Beemsterboer P, Rietbergen J, et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region). Prostate 1999;39:316–322.

    Article  PubMed  CAS  Google Scholar 

  21. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997;277:1452–1455.

    Article  PubMed  CAS  Google Scholar 

  22. Schröder FH, van der Cruijsen-Koeter I, Koning HJ, et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806–812.

    Article  PubMed  Google Scholar 

  23. Schröder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90(23):1817–1823.

    Article  PubMed  Google Scholar 

  24. Donovan JL, Hamdy FC, Neal DE, et al. Prostate testing for cancer and treatment (Protect) feasibility study. Health Technol Assess 2003;7(14).

    Google Scholar 

  25. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer: Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med 2002;347:781–789.

    Article  PubMed  Google Scholar 

  26. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. Scandinavian Prostatic Cancer Group Study Number 4. N Engl J Med 2002;347:790–796.

    Article  PubMed  Google Scholar 

  27. Begg CB, Riedel CR, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138–1144.

    Article  PubMed  Google Scholar 

  28. Wilt TJ, Brawer MK. The prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Huntington) 1997;11(8):1133–1139.

    PubMed  CAS  Google Scholar 

  29. Donovan J, Mills N, Smith M, et al. Improving design and conduct of randomised trials by embedding them in qualitative research: Protect (Prostate Testing for Cancer and Treatment) study. BMJ 2002;325:766–770.

    Article  PubMed  Google Scholar 

  30. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet 2000;355:1788–1789.

    Article  PubMed  CAS  Google Scholar 

  31. Schröder FH, Wildhagen MF. Screening for prostate cancer: evidence and perspectives. BJU Int 2001;88:811–817.

    Article  PubMed  Google Scholar 

  32. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58:417–424.

    Article  PubMed  CAS  Google Scholar 

  33. Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740–745.

    Article  PubMed  Google Scholar 

  34. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. European Randomized Screening for Prostate Cancer (ERSPC) Trial; International Prostate Cancer Screening Trials Evaluation Group. Large-scale randomised prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer 2002;97:237–244.

    Article  PubMed  CAS  Google Scholar 

  35. Chapple A, Ziebland S, Sheppard S, et al. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. BMJ 2002;325:737–739.

    Article  PubMed  Google Scholar 

  36. Thornton H, Dixon-Woods M. Prostate specific antigen testing for prostate cancer. BMJ 2002;325:725–726.

    Article  PubMed  Google Scholar 

  37. Perrin P. Personal communication, 2002.

    Google Scholar 

  38. Mettlin C, Jones G, Avetett H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related check-up: prostate and endometrial cancers. Cancer J Clin 1993;43:42–46.

    CAS  Google Scholar 

  39. American Urological Association. Early detection of prostate and cancer use of transrectal ultrasound. In: AUA, ed. American Urological Association 1992 Policy Statement Book. Baltimore: American Urological Association, 1992:4–20.

    Google Scholar 

  40. U.S. Preventative Service Task Force. Screening for Prostate Cancer: Guide to Clinical Preventative Services, 2nd ed. Baltimore: Williams & Wilkins, 1996:119.

    Google Scholar 

  41. American College of Physicians. Screening for prostate cancer. Ann Intern Med 1997;126:480–484.

    Google Scholar 

  42. Chadwick DJ, Kemple T, Astley JP, et al. Pilot study of screening for prostate cancer in general practice. Lancet 1991;338:613–616.

    Article  PubMed  CAS  Google Scholar 

  43. Selley S, Donovan J, Faulkner A, et al. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997;1(2):i, 1–96.

    PubMed  CAS  Google Scholar 

  44. Cheamberlain J, Melia J, Moss S, et al. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997;1(3):i–iv, 1–53.

    Google Scholar 

  45. Milburn A. http://www.doh.gov.uk/cancer, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Urology Unit, Division of Clinical Sciences (South), School of Medicine & Biomedical Sciences, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK

    Joshua Phillips MBChB, MRCS & Freddie C. Hamdy MB ChB, MD, FRCS

Authors
  1. Joshua Phillips MBChB, MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Freddie C. Hamdy MB ChB, MD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Hammersmith Campus, Imperial College London, London, UK

    Jonathan Waxman BSc, MD, FRCP (Professor of Oncology) (Professor of Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

Phillips, J., Hamdy, F.C. (2005). Screening for Prostate Cancer. In: Waxman, J. (eds) Urological Cancers. Springer, London. https://doi.org/10.1007/1-84628-015-X_3

Download citation

  • DOI: https://doi.org/10.1007/1-84628-015-X_3

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-911-1

  • Online ISBN: 978-1-84628-015-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation